Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

Covid vaccine provisionally approved in Australia for children aged six months to six years

Moderna’s paediatric dose will become available only after Australian Technical Advisory Group on Immunisation gives advice

The Guardian - AU

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

A dire moment in the pandemic ... was the chance he'd been waiting for

How Sotiris Missailidis, head of R&D in Brazil's vaccine agency, used the COVID crisis to push through a game-changing effort for middle-income countries to invent their own mRNA vaccine.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Covid vaccine protection ‘short lived,’ booster doses essential, study confirms

‘Continual updating of our vaccinations and booster shots is critical,’ scientists say

The Independent UK

Australia has ordered millions more COVID vaccines than it needs. What are the options to deal with them?

Australia has used less than a quarter of the hundreds of millions of COVID-19 vaccine doses it bought. What will happen to the rest?

ABC News

Here's How To Trade This Pattern On BlackBerry, Moderna And Palantir Stocks

BlackBerry Ltd (NYSE: BB), Moderna Inc (NASDAQ: MRNA) and Palantir Technologies Inc (NYSE: PLTR) have been showing strength in

Benzinga

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

COVID-19 vaccines targeting the Omicron variant are on the way — but it could be worth getting a fourth dose now

Omicron is now the dominant strain of COVID-19 around the world and boosters targeting this variant are getting closer to being released.

ABC News

The public deserves a return on the medicines governments support

Public money directly and indirectly supports pharmaceutical innovation. Governments need to ensure the public gets a fair return on its investment.

360info

Novavax’s COVID vaccine gets US nod as latest pandemic weapon

Novavax Inc.’s COVID-19 vaccine was cleared by U.S. regulators, giving Americans another tool against the virus as cases start to rise again.

Tribune News Service

These Brazilian besties are inventing an mRNA vaccine as a gift to the world

Pfizer and Moderna have refused to divulge details of how to make their cutting-edge COVID shots. Here's what two scientists — and longtime best friends — are doing about it.

WEKU

Moderna Whale Trades Spotted

Benzinga

Experts say there are a number of factors to weigh up about getting a fourth dose of a COVID-19

As millions more people become eligible for a fourth COVID vaccine dose, you might be asking whether you should book in for it or wait for Omicron-specific vaccines still being developed.

ABC News

Thinking of mixing and matching COVID-19 vaccine booster shots? There doesn't seem to be much point

Most people will have the Moderna or the Pfizer vaccine for their fourth dose. But the Doherty Institute's head of vaccine and immunisation research says there's practically no difference between them.

ABC News

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

Omicron boosters could be here by fall

As viruses morph and adapt, there's a greater call for targeted vaccines and boosters

The New Daily

COVID boosters: When Australians might be able to get their fourth jabs

With a third Omicron wave approaching, the wider Australian population may soon be able to get their second COVID booster shots.

Benzinga

This Is What Whales Are Betting On Moderna

The Conversation

COVID vaccines: our current shots could soon be updated to target new variants – an immunology expert explains

More than two years into the pandemic, SARS-CoV-2, the virus that causes COVID-19, continues to challenge us. Its ability to rapidly mutate has seen the evolution of increasingly infectious variants that are getting better at hiding from our immune response.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Peering Into Moderna's Recent Short Interest

Moderna's (NASDAQ:MRNA) short percent of float has fallen 4.65% since its last report. The company recently reported that it has 14.76 million shares sold short, which is 4.31% of all regular shares that are available for trading.

Chronicle Live

New 'super booster' Covid vaccine could be approved for use in UK within days

Moderna has created a new type of jab, codenamed 214, which is said to be more effective than previous vaccines, according to reports

Wales Online

30million people could get new Covid super booster codenamed 214

The jab engineered to tackle the new variants causing a summer wave is expected to be approved for use in the UK

The Guardian - UK

What’s the UK’s booster policy ahead of a feared autumn Covid wave?

Tweaked vaccines to tackle Omicron are in trials as JCVI finalises advice for vulnerable groups

Daily Mirror

New Moderna 'super-booster' jab to target Wuhan and Omicron strains 'coming in Autumn'

The jab, known as “214”, is bivalent, which means it helps build immunity to both the original Wuhan strain and the Omicron variants

The Independent UK

Covid: Urgent call to update vaccines to target variants as cases rise to near-record levels

The case is growing to tweak the jabs to target more tranmissible Omicron variants, experts say

Benzinga

What Are Whales Doing With Moderna

A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 19 strange trades.

1 … 19 20 21 22

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.